IndustryCompany release

Bio-Rad Q3 sales edge up 0.5% to $656.4M as Sartorius stake lifts profit

🇺🇸 Bio-Rad Laboratories, Inc. (BIO) · Wed 04 Nov 2026

Clinical Diagnostics growth offset a decline in Life Science, while a fair-value change on the Sartorius holding drove GAAP net income of $458.6 million; full-year guidance is unchanged.

Bio-Rad Laboratories reported third-quarter 2026 net sales of $656.4 million on 4 November 2026, a rise of 0.5%, according to the company's results announcement.

The two main segments moved in opposite directions. Clinical Diagnostics grew 2.7%, while Life Science fell 2.8%.

GAAP net income was $458.6 million. The company attributed the result largely to a fair-value change in its investment in Sartorius AG, so the figure does not reflect operating performance alone.

Bio-Rad left its full-year 2026 outlook as it was. It still expects currency-neutral revenue to range from a 3.0% decline to 0.5% growth, with a non-GAAP operating margin of roughly 10% to 12%.

The source material available to VigiEye was limited to these headline figures, so no further detail on product lines, regions or drivers of the segment trends is reported here.

What it means for your team

  • Diagnostics and life-science customers may see differing demand patterns at Bio-Rad: clinical diagnostics growth of 2.7% contrasts with a 2.8% decline in Life Science.
  • Teams assessing supplier stability should note that GAAP net income was inflated by a Sartorius investment fair-value change and is not a guide to underlying trading.
  • Unchanged guidance (currency-neutral revenue from -3.0% to +0.5%, non-GAAP operating margin about 10-12%) signals no change in the company's full-year expectations.

Company's press release (SEC filing): Bio-Rad Laboratories, Inc. ↗

Article written by VigiEye from the official source (Bio-Rad Laboratories, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →